A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 7, Issue 289, Pages 289ra82-289ra82
Publisher
American Association for the Advancement of Science (AAAS)
Online
2015-05-28
DOI
10.1126/scitranslmed.aaa5693
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
- (2014) H. K. Lee et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials
- (2014) D. A. Pollyea et al. HAEMATOLOGICA
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
- (2014) I Pizzitola et al. LEUKEMIA
- Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice
- (2014) K. L. Gutbrodt et al. MOLECULAR CANCER THERAPEUTICS
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
- (2013) Mohamed A. Kharfan-Dabaja et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
- (2013) A. Mardiros et al. BLOOD
- AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
- (2013) E. K. Keeton et al. BLOOD
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
- (2013) Sarah Tettamanti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
- (2012) S.-R. Kuo et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
- (2011) F. Vergez et al. HAEMATOLOGICA
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age
- (2011) W. W. Pang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
- (2010) Markus Kügler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma
- (2010) Jonathan R. Fromm CYTOMETRY PART B-CLINICAL CYTOMETRY
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
- (2009) R. Le Dieu et al. BLOOD
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
- (2008) Arthur Frankel et al. LEUKEMIA & LYMPHOMA
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started